Cosentyx is a medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a biologic drug that works by blocking a protein called interleukin-17A, which is involved in inflammation.

According to drugpatentwatch.com [1], Cosentyx was first approved by the FDA in January 2015. Since then, there have been no major updates or changes to the drug's formulation or dosage.

However, clinical studies have shown that Cosentyx can be effective in treating psoriatic arthritis. In a study published in the Journal of Rheumatology [3], patients who received Cosentyx had significant improvements in joint pain, swelling, and function compared to those who received a placebo. Another study published in the New England Journal of Medicine [2] found that Cosentyx was more effective than a placebo in treating psoriasis.

Additionally, the official Cosentyx website [2] provides patient stories and treatment results for psoriatic arthritis. These stories suggest that many patients have seen improvements in joint pain, stiffness, and swelling since starting Cosentyx.

In summary, while there have been no major updates to Cosentyx since its initial approval, clinical studies and patient stories suggest that it can be an effective treatment for psoriatic arthritis and psoriasis. If you are considering Cosentyx as a treatment option, it is important to discuss the potential benefits and risks with your healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.cosentyx.com/psoriatic-arthritis/treatment-results
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842331/